India Patent Office denies patent for prostate cancer drug sold under brand name Xtandi, generic name enzalutamide
Updated
According to this story, the India Patent Office has denied a patent for the prostate cancer drug sold under the brand name Xtandi (generic name Enzalutamide). Opponents of the patent claimed it was a new form of a known substance, and not eligible in India under Section 3(d) of its patent act.